AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Nichts die sieht man doch.. rote Zahlen

Was denn passiert

Läuft bei abcellera

https://investors.abcellera.com/news/news-releases/2022/AbCellera-and-AbbVie-Partner-to-Advance-New-Antibody-Therapies/default.aspx

Wieder am abkacken 😔

https://www.instagram.com/reel/ClonqLYL7H1/?igshid=MDJmNzVkMjY=

https://endpts.com/rallybio-abcellera-form-new-partnership-around-antibodies-for-rare-disease/

https://biv.com/article/2022/11/patent-partnership-court-fight-looms-biotech?amp

Wtf was aufeinmal hier loss?? Von 14 usd auf 11.20 usd gefallen

. https://stock.vi.app/biotechnology/regeneron-and-abcellera-collaborate-on-second-antibody-program/

AbCellera Biologics - ABCL Price Target & Analyst Ratings https://www.marketbeat.com/stocks/NASDAQ/ABCL/price-target/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia

Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29. Truist Securities analyst Robyn Karnauskas initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $29. https://www.webullapp.com/news-detail/7660739051940864?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=StockNews&tickerId=950178304&disSymbol=ABCL&theme=1&color=2&hl=en&android_sdk_int=29&canary-version=&_v=1&sp=1&statusBarHeightV2=36&wbFontSetting=medium&wbFontUnit=30&wbFontSize=30&isSubsNews=false

💯

https://investors.abcellera.com/news/news-releases/2022/AbCellera-Presents-New-Data-on-Further-Development-and-Characterization-of-T-Cell-Engager-Platform-at-SITC-2022/default.aspx

https://investors.abcellera.com/news/news-releases/2022/AbCellera-Reports-Q3-2022-Business-Results/default.aspx